

AMENDMENTS TO THE CLAIMS

1-41. (Cancelled)

42. (Withdrawn – currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of Ac, H, and ASAL, optionally iodinated in position 5 to yield the group 2-hydroxy-4-azido-5-iodo benzoyl.

43. (Withdrawn – currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R₇ is NH₂.

44-49. (Cancelled)

50. (Currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_g is the amino acid side chain of Asn, D-4Hyp, or L-/D-Pro when said compound is a linear peptide, wherein, when R_g is the amino acid side chain of D-4Hyp or L-/D-Pro, the side chain is cyclized by attachment to the N atom bonded to the C atom to which R_g is attached.


51. (Withdrawn - currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_h is the amino acid side chain of ~~Pro~~, Pro or D-Pro, or D-Hyp, wherein the side chain is cyclized by attachment to the N atom bonded to the C atom to which R_h is attached.


52. (Withdrawn – currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_i is the amino acid side chain of Tyr ~~or D-Tyr~~.

53. (Withdrawn – currently amended) The compound according to claim 163, or a pharmaceutically acceptable salt thereof, wherein R_j is the amino acid side chain of Asn ~~or Gln~~.

54-162. (Cancelled).

163. (Currently Amended) A compound having the formula:





or a retro form, an all D form, or a retro all D form thereof, said compound optionally being cyclic through a covalent bond between N* and C*;

wherein:

X is H, Ac, TFa, DBF, ASAL optionally iodinated, or HP;

l and n are 1;

each of j, k, l, m, n, p, p and q is are independently 0 or 1;

~~R_a is the side chain of Hyp or Pro, which is cyclized by attachment to the N atom bonded to the C atom to which R_a is attached;~~

~~R_b is the side chain of Hyp or Pro, which is cyclized by attachment to the N atom bonded to the C atom to which R_a is attached;~~

R_c is the side chain of Gly ~~or Sar~~;

R_d is the side chain of Ala, ~~D-Ala~~, or Gly;

~~R_e is the acid side chain of Ala;~~

R_f is the acid side chain of Ala, ~~Sar~~, or Gly;

R_g is the side chain of L-Hyp, D-Hyp, Pro, D-Pro, Ncg, A2C, ~~Sar~~, Gly, Asn, ~~D-Asn~~, T4c, or Pc, ~~Lys~~, or Thio-Pro if the compound is a cyclic compound, or R_g is the side

chain of D-Hyp, Pro, D-Pro, Ncg, A2C, ~~Sar~~, Gly, Asn, ~~D-Asn~~, T4c, or Pc, ~~Lys, or Thio-Pro~~ if the compound is a linear peptide, wherein said side chain of L-Hyp, D-Hyp, Pro, D-Pro, or Thio-Pro is cyclized by attachment to the N atom bonded to the C atom to which R_g is attached;

R_h is the side chain of Pro, D-Pro, or Ala, ~~D-Hyp, Asn, or Thio-Pro~~, wherein said side chain of ~~Pro~~, Pro or D-Pro, ~~D-Hyp, or Thio-Pro~~ is cyclized by attachment to the N atom bonded to the C atom to which R_h is attached;

R_i is the side chain of ~~Gly, Phe, D-Phe, Tyr~~, Tyr or D-Tyr, wherein the aromatic ring of said ~~Phe, D-Phe, Tyr, or D-Tyr~~ side chain is optionally substituted with one or more halogen groups;

R_j is the side chain of ~~Gln~~, Gln or Asn, ~~D-Asp, or Cys~~;

R₇ is OH or NH₂, or is absent if the compound is cyclized between N* and C*, or a pharmaceutically acceptable salt thereof.

164. (Cancelled)

165. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Hyp-Pro-Tyr-Asn-) (SEQ ID NO:287), or a pharmaceutically acceptable salt thereof.

166. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is cyclo(-Tyr-Pro-4Hyp-Gly-Ala-Gly-Asn-) (SEQ ID NO:174), or a pharmaceutically acceptable salt thereof.

167. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Asn-) (SEQ ID NO:288), or a pharmaceutically acceptable salt thereof.

168. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Gln-), or a pharmaceutically acceptable salt thereof.

169. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Pro-Pro-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

170. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Pro-D-Pro-Gly-D-Ala-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

171. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is Ac-D-Tyr-D-Hyp-D-Hyp-Gly-D-Ala-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

172. (Withdrawn – currently amended) The compound of claim 163, wherein said compound is Gly-Ala-Gly-Asn-Tyr-NH₂ (SEQ ID NO:254), or a pharmaceutically acceptable salt thereof.

173. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Ala-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

174. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Gly-Ala-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

175. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Ac-Ala-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

176. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Ac-Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

177. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Gly-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

178. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Ac-D-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

179. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is D-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

180. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Gly-D-Asn-Tyr, or a pharmaceutically acceptable salt thereof.

181. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Tyr-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

182. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Gly-Gly-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

183. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Gly-D-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

184. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Tyr-D-Asn-Gly, or a pharmaceutically acceptable salt thereof.

185. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Ac-Tyr-D-Asn-Gly, or a pharmaceutically acceptable salt thereof.

186. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Ac-Gly-D-Asn-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

187. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

188. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Ac-Tyr-D-Asn-Gly-NH₂, or a pharmaceutically acceptable salt thereof.

189. (Withdrawn – currently amended) The compound of claim ~~463~~ 195, wherein said compound is Gly-Ala-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

190. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Ac-Gly-Ala-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.


191. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Gly-Asp-Tyr-NH₂, or a pharmaceutically acceptable salt thereof.

192. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Tyr-Asn-Gly, or a pharmaceutically acceptable salt thereof.

193. (Withdrawn – currently amended) The compound of claim ~~163~~ 195, wherein said compound is Tyr-Asp-Gly, or a pharmaceutically acceptable salt thereof.

194. (Currently amended) The compound of claim 163, or a pharmaceutically acceptable salt thereof, wherein X is Ac or H and R_g is selected from the group consisting of Pro, D-Pro, Hyp, D-Hyp, Gly, or Asn.

195. (New) A compound comprising the formula:



a retro, all-D, or retro all-D form thereof; or a pharmaceutically acceptable salt thereof;

wherein

n is 0 or 1;

X is H or Ac;

R_d is the amino acid side chain of Ala or Gly;


R_f is the side chain of Ala or Gly;

R_g is the side chain of any amino acid except the side chain of L-4Hyp or a moiety of formula II or IIa;

R_i is the amino acid side chain of Tyr; and


R₇ is OH or NH₂;

wherein formula II is represented by:



wherein n is an integer having the value 3, 4, or 5, and R represents an optional substituent selected from the group consisting of halogen, phenyl, hydroxy, NH₂, and C(1-6)alkyl, and

wherein formula IIa is represented by



wherein n is an integer having the value 0, 1, 2, and 3, p is an integer having the value 0, 1, 2, and 3, Z represents O or S, and R represents an optional substituent selected from the group consisting of halogen, phenyl, hydroxy, NH₂ and C(1-6)alkyl.

196. (New) The peptide of claim 195, or a pharmaceutically acceptable salt thereof, wherein R_g is the amino acid side chain of Asn.